Literature DB >> 27165675

Pretreatment Hematologic Findings as Novel Predictive Markers for Facial Palsy Prognosis.

Koichiro Wasano1, Taiji Kawasaki2, Sayuri Yamamoto2, Shuta Tomisato2, Seiichi Shinden3, Toru Ishikawa3, Shujiro Minami4, Takeshi Wakabayashi4, Kaoru Ogawa5.   

Abstract

OBJECTIVE: To examine the relationship between prognosis of 2 different facial palsies and pretreatment hematologic laboratory values. STUDY
DESIGN: Multicenter case series with chart review.
SETTING: Three tertiary care hospitals. SUBJECTS AND METHODS: We examined the clinical records of 468 facial palsy patients who were treated with an antiviral drug in combination with either oral or intravenous corticosteroids in participating hospitals between 2010 and 2014. Patients were divided into a Bell's palsy group or a Hunt's palsy group. We used the Yanagihara facial nerve grading system to grade the severity of facial palsy. "Recovery" from facial palsy was defined as achieving a Yanagihara score ≥36 points within 6 months of onset and having no accompanying facial contracture or synkinesis. We collected information about pretreatment hematologic findings, demographic data, and electrophysiologic test results of the Bell and Hunt group patients who recovered and those who did not. We then compared these data across the 2 palsy groups.
RESULTS: In the Bell's palsy group, recovered and unrecovered patients differed significantly in age, sex, electroneuronography score, stapedial muscle reflex, neutrophil rate, lymphocyte rate, neutrophil-to-lymphocyte ratio, and initial Yanagihara score. In the Hunt's palsy group, recovered and unrecovered patients differed in age, electroneuronography score, stapedial muscle reflex, monocyte rate, platelet count, mean corpuscular volume, and initial Yanagihara score.
CONCLUSIONS: Pretreatment hematologic findings, which reflect the severity of inflammation and bone marrow dysfunction caused by a virus infection, are useful for predicting the prognosis of facial palsy. © American Academy of Otolaryngology—Head and Neck Surgery Foundation 2016.

Entities:  

Keywords:  Bell’s palsy; Yanagihara score; biomarker; bone marrow dysfunction; facial palsy; prognosis; severity of virus infection

Mesh:

Substances:

Year:  2016        PMID: 27165675     DOI: 10.1177/0194599816646552

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  6 in total

1.  Intratympanic Steroid Treatment of Bell's Palsy in Patients with Comorbid Disease: A Preliminary Report.

Authors:  Deniz Demir; Sena Genç; Mehmet Güven; Mahmut Sinan Yılmaz; Ahmet Kara; Ünal Erkorkmaz
Journal:  J Int Adv Otol       Date:  2020-04       Impact factor: 1.017

2.  Hematological Findings in Patients with Acute Peripheral Facial Palsy.

Authors:  Su Jin Kim; Ho Yun Lee
Journal:  J Int Adv Otol       Date:  2020-12       Impact factor: 1.017

3.  The research for the function evaluation of facial nerve and the mechanisms of rehabilitation training.

Authors:  Han Si-Yi; Wang Ling; Yu Hai-Bo; Gou Yan-Hua; Zhong Wei-Zheng; Huang Xing-Xian; Zhang Shao-Yun; Liu Yong-Feng; Chen Yi-Rong
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

4.  Association of Patients' Characteristics with Acupuncture Treatment Outcomes in Treating Bell's Palsy: Results from a Randomised Controlled Trial.

Authors:  Xianjun Xiao; Qianhua Zheng; Yunzhou Shi; Leixiao Zhang; Ling Zhao; Siyuan Zhou; Wei Zhang; Wei Cao; Ying Liu; Ying Li
Journal:  Evid Based Complement Alternat Med       Date:  2019-08-15       Impact factor: 2.629

5.  The utility of peripheral blood leucocyte ratios as biomarkers in infectious diseases: A systematic review and meta-analysis.

Authors:  Clark D Russell; Arun Parajuli; Hugo J Gale; Naomi S Bulteel; Philipp Schuetz; Cornelis P C de Jager; Anne J M Loonen; Georgios I Merekoulias; J Kenneth Baillie
Journal:  J Infect       Date:  2019-02-22       Impact factor: 6.072

Review 6.  Role of Biomarkers as Prognostic Factors in Acute Peripheral Facial Palsy.

Authors:  Tae Hoon Kim; Seung Geun Yeo; Jae Yong Byun
Journal:  Int J Mol Sci       Date:  2021-12-28       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.